CN117257915A - 一种红细胞搭便车偶联物及其制备方法和应用 - Google Patents
一种红细胞搭便车偶联物及其制备方法和应用 Download PDFInfo
- Publication number
- CN117257915A CN117257915A CN202311267933.2A CN202311267933A CN117257915A CN 117257915 A CN117257915 A CN 117257915A CN 202311267933 A CN202311267933 A CN 202311267933A CN 117257915 A CN117257915 A CN 117257915A
- Authority
- CN
- China
- Prior art keywords
- rapa
- conjugate
- peg
- dved
- red blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 79
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 31
- 238000011282 treatment Methods 0.000 claims abstract description 28
- 230000036542 oxidative stress Effects 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 23
- 239000000126 substance Substances 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 12
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 11
- 229920001184 polypeptide Polymers 0.000 claims abstract description 11
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 10
- 108091008324 binding proteins Proteins 0.000 claims abstract description 7
- 238000012377 drug delivery Methods 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 37
- 239000002202 Polyethylene glycol Substances 0.000 claims description 18
- 230000004044 response Effects 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 108010033276 Peptide Fragments Proteins 0.000 claims description 7
- 102000007079 Peptide Fragments Human genes 0.000 claims description 7
- 102000005600 Cathepsins Human genes 0.000 claims description 6
- 108010084457 Cathepsins Proteins 0.000 claims description 6
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 6
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 6
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 6
- 229960002930 sirolimus Drugs 0.000 claims description 6
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 4
- 150000002019 disulfides Chemical class 0.000 claims description 4
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 125000002228 disulfide group Chemical group 0.000 claims description 2
- 229960005167 everolimus Drugs 0.000 claims description 2
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims description 2
- 229960005330 pimecrolimus Drugs 0.000 claims description 2
- 229960001967 tacrolimus Drugs 0.000 claims description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 20
- 239000008280 blood Substances 0.000 abstract description 20
- 230000006378 damage Effects 0.000 abstract description 16
- 208000027418 Wounds and injury Diseases 0.000 abstract description 14
- 208000014674 injury Diseases 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 10
- 230000008569 process Effects 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 2
- 241001506137 Rapa Species 0.000 description 39
- 238000006243 chemical reaction Methods 0.000 description 29
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 101800000068 Antioxidant peptide Proteins 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 201000011040 acute kidney failure Diseases 0.000 description 12
- 230000004900 autophagic degradation Effects 0.000 description 12
- 210000003734 kidney Anatomy 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 11
- 229960004316 cisplatin Drugs 0.000 description 11
- 239000011347 resin Substances 0.000 description 11
- 229920005989 resin Polymers 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- -1 superoxide anions Chemical class 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 9
- 208000009304 Acute Kidney Injury Diseases 0.000 description 9
- 102000003952 Caspase 3 Human genes 0.000 description 9
- 108090000397 Caspase 3 Proteins 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000006285 cell suspension Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 7
- 208000033626 Renal failure acute Diseases 0.000 description 7
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 7
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 208000028867 ischemia Diseases 0.000 description 7
- 210000001700 mitochondrial membrane Anatomy 0.000 description 7
- 238000010172 mouse model Methods 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- 206010008118 cerebral infarction Diseases 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 210000003470 mitochondria Anatomy 0.000 description 6
- 230000010410 reperfusion Effects 0.000 description 6
- 238000003746 solid phase reaction Methods 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 229940100601 interleukin-6 Drugs 0.000 description 5
- 229940118019 malondialdehyde Drugs 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 201000006474 Brain Ischemia Diseases 0.000 description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 206010063837 Reperfusion injury Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000002438 mitochondrial effect Effects 0.000 description 4
- 210000003463 organelle Anatomy 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 238000002390 rotary evaporation Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 235000010378 sodium ascorbate Nutrition 0.000 description 4
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 4
- 229960005055 sodium ascorbate Drugs 0.000 description 4
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102100024178 Microtubule-associated proteins 1A/1B light chain 3A Human genes 0.000 description 3
- 101800001821 Precursor of protein E3/E2 Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100020814 Sequestosome-1 Human genes 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 102000023732 binding proteins Human genes 0.000 description 3
- 238000011278 co-treatment Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 3
- 101800002664 p62 Proteins 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 2
- 102000003954 Autophagy-Related Proteins Human genes 0.000 description 2
- 108010082399 Autophagy-Related Proteins Proteins 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000012650 click reaction Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000003657 middle cerebral artery Anatomy 0.000 description 2
- 230000007971 neurological deficit Effects 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- UUGXJSBPSRROMU-UHFFFAOYSA-N 2,3-dimethoxy-5-methyl-2-<(all-E)-3',7',11',15',19',23',27',31',35'-nonamethylhexatriaconta-2',6',10',14',18',22',26',30',34',nonaenyl>cyclohexa-2,5-dien-1,4-dion Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O UUGXJSBPSRROMU-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 235000005811 Viola adunca Nutrition 0.000 description 1
- 240000009038 Viola odorata Species 0.000 description 1
- 235000013487 Viola odorata Nutrition 0.000 description 1
- 235000002254 Viola papilionacea Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 210000000269 carotid artery external Anatomy 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 1
- 229950009041 edaravone Drugs 0.000 description 1
- 238000009297 electrocoagulation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- OKISBDHRUPZLOC-UHFFFAOYSA-N gallin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C(O)=C2OC2=C(O)C(O)=CC=C21 OKISBDHRUPZLOC-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- NWKYZYGOSPOKDY-UHFFFAOYSA-N n,n-dimethylformamide;pyridine Chemical compound CN(C)C=O.C1=CC=NC=C1 NWKYZYGOSPOKDY-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 238000011311 validation assay Methods 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明属于医药技术领域,具体的说是一种红细胞搭便车型(SS31‑Rapa)偶联物及其制备方法和在药物递送领域和治疗氧化应激损伤相关疾病中的应用。偶联物结构为S‑C‑L‑R,其中,S为抗氧化功能的多肽,C为敏感型连接臂,L为Linker,R为能够与红细胞的结合蛋白靶点结合的物质;或,偶联物的盐。相比与传统的红细胞搭便车类制剂,本发明中的SS31‑Rapa偶联物无需后续处理,可直接增溶后注射,在血液内蓄积于红细胞中,完成红细胞搭便车的过程。无需纳米制剂的制备和引入其他辅料。
Description
技术领域
本发明属于医药技术领域,具体的说是一种红细胞搭便车型(SS31-Rapa)偶联物及其制备方法和在药物递送领域和治疗氧化应激损伤相关疾病中的应用。
背景技术
活性氧(Reactive oxygen species,简称ROS)是一系列氧气未完全还原形式的总成,在细胞内线粒体中通过三羧酸循环和脂肪酸氧化等过程产生,主要包括超氧阴离子(O2 ·-)、过氧化氢(H2O2)、单线态氧(1O2)和羟基自由基(·OH)。在正常机体中,ROS可以调节氧化还原平衡,对维持机体的各项生理功能起着十分重要的作用。过量产生的ROS会造成线粒体内膜上特有的心磷脂过氧化并干扰线粒体内膜上微域的稳定性进而引起线粒体内膜的破损。这会导致位于线粒体内膜上的呼吸超复合物破损和细胞色素C从线粒体内膜上分离,大幅度降低线粒体内ATP合成的速度,并且增加在呼吸链中电子的遗失,进一步促进ROS的产生。除此之外,这一过程还会导致线粒体内膜的通透性发生改变,导致细胞色素C和线粒体DNA等促凋亡和促炎性细胞因子进入细胞内,并导致细胞死亡。目前,大量研究表明,ROS过量产生所引起氧化应激损伤在急性肾损伤、神经退行性疾病、手术后的缺血再灌注损伤、休克和炎症反应的发生中均扮演着十分重要的角色。因此,清除ROS,保护线粒体的结构与功能成为了治疗氧化应激损伤导致的疾病的重要治疗方法。目前,SS抗氧化肽、CoQ10和Mito-TEMPO等线粒体靶向ROS清除剂以及没食子素、胆红素、姜黄素、槲皮素、奥替拉普和依达拉奉等抗氧化剂已经广泛应用于治疗ROS过量产生而引起的氧化应激损伤相关疾病。
在这其中,SS31(Arg-Dmt-Lys-Phe-NH2),作为一种抗氧化四肽,目前已经在临床试验中用于治疗多种线粒体相关的疾病,包括原发性线粒体肌病、巴氏综合征、心力衰竭和肾动脉血管手术后的缺血再灌注损伤等。SS31可以通过静电力和疏水作用力特异性结合线粒体内膜上特有的心磷脂,维持线粒体内膜的內脊和微域的稳定,进而保护线粒体的结构与功能,防止氧化应激引起的细胞损伤。然而,作为一种合成类多肽,SS31较差的药动学性质使得其并未获得理想的临床试验结果。目前,研究人员尝试改变SS抗氧化肽的氨基酸序列来改善其药动学性质,以获得更好的治疗效果。
发明内容
本发明为改善抗氧化肽SS31的药动学特性和提高其在氧化应激引起的相关疾病治疗效果提供了新的策略和更多的选择,满足临床中对高效治疗急性氧化应激引起的相关疾病的迫切需求;进而提供一种红细胞搭便车型(SS31-Rapa)偶联物及其制备方法和在药物递送领域和治疗氧化应激损伤相关疾病中的应用。
为实现上述目的,本发明采用技术方案为:
一种红细胞搭便车型偶联物,偶联物结构为S-C-L-R,其中,S为抗氧化功能的多肽,C为敏感型连接臂,L为Linker,R为能够与红细胞的结合蛋白靶点结合的物质;
或,偶联物的盐。
所述抗氧化功能的多肽为SS31(Arg-Dmt-Lys-Phe-NH2)、SBT-20(Phe-Arg-Phe-Lys-NH2)、SBT-68(Arg-Dmt-Ala-Phe-NH2)、SBT-100(Arg-Dmt-His-Phe-NH2)或SBT-131(Orn-Dmt-Lys-Phe-NH2)。
所述敏感型连接臂为二硫醚衍生物、基质金属蛋白酶或组织蛋白酶响应肽;其中,二硫醚衍生物为酮缩硫醇;基质金属蛋白酶响应肽为GPLGLAGC肽段;组织蛋白酶响应肽为DVED肽段。
所述Linker的结构中一端含与自裂解结构相连的活性位点,另一端含能够与红细胞内的结合蛋白靶点结合的物质结合的活性位点,且,循环长度为PEG4-PEG10。
所述敏感型连接臂为二硫醚衍生物时,Linker中与其结合一端的活性位点为氨基或羟基,另一端结合位可以与红细胞内结合物质连接(R),且,循环长度为PEG4-PEG10;敏感型连接臂为基质金属蛋白酶敏感肽时Linker中与其结合一端的活性位点为氨基或羟基,另一端结合位点可以与红细胞内结合物质连接,且,循环长度为PEG4-PEG10;敏感型连接臂为组织蛋白酶响应肽时Linker中与其结合一端的活性位点为氨基或羟基,另一端结合位点可以与红细胞内结合物质连接,且,循环长度为PEG4-PEG10。
所述能够与红细胞内的结合蛋白靶点结合的物质为雷帕霉素、他克莫司(FK506)、吡美莫司或依维莫司等。
所述抗氧化功能的多肽为SS31、SBT-20或SBT68,优选SS31;所述敏感型连接臂为酮缩硫醇、GPLGLAGC肽段或DVED肽段,优选DVED肽;所述Linker为PEG6、PEG8或PEG10,优选PEG6;所述能够与红细胞内的结合蛋白靶点结合的物质为雷帕霉素或他克莫司,优选雷帕霉素。
上述红细胞搭便车型偶联物的制备方法,以SS31为抗氧化肽,caspase-3响应断裂的DVED肽段作为敏感键,PEG6作为Linker所构成的SS31-Rapa偶联物(SS31-DVED-Rapa)的结构。其具体结构如下:
方法如下:
(1)将丙炔醇乙氧基化合物三氟甲磺酸化得到三氟甲磺酸-2-丙炔基氧基乙酯。再将其与Rapa在DIPEA的催化下反应生成Alkynyl-Rapa。
(2)将Ramage Amide AM resin树脂溶胀活化,采用固相肽合成的方法依次合成SS31和DVED敏感肽。在固相合成柱中,使用DIPEA催化,将N3-PEG6-CH2CH2COOH与肽段连接。最后将产物整体从树脂上切割下来,经制备液相分离纯化得到SS31-DVED-PEG6-N3。
(3)将Alkynyl-Rapa与SS31-DVED-PEG6-N3溶于甲醇,在CuSO4和抗坏血酸钠的催化下使炔基和叠氮发生click反应,后经纯化得到终产物。
更具体为:
(1)合成2-丙炔基氧基乙基化修饰的Rapa(Alkynyl-Rapa):将1倍量的丙炔醇乙氧基化合物溶于二氯甲烷中,在-50℃下加入1~2倍量的2,6-二甲基吡啶和1~2倍量的三氟甲磺酸酐,在-10℃下反应1~2h,反应结束后用乙酸乙酯和正己烷的混合液与饱和NaCl萃取,有机层用饱和NaCl洗涤三次后用无水Na2SO4干燥过夜再通过减压旋转蒸发法除去有机溶剂,得到粗产物,通过硅胶柱层析法,以正己烷和乙酸乙酯(9:1)为洗脱剂进行纯化,得到产物三氟甲磺酸-2-丙炔基氧基乙酯。将1倍量的Rapa溶于氯仿中,在-10℃,N2保护的条件下加入2~8倍量的三氟甲磺酸-2-丙炔基氧基乙酯和2-8倍量的DIPEA,然后升温至50~80℃,继续搅拌反应1~2h,反应后使用乙酸乙酯和H2O萃取,收集有机层并用饱和NaCl溶液洗涤3次后,使用无水Na2SO4干燥过夜后,通过硅胶柱层析法进行分离,以正己烷和乙酸乙酯(2:1)为洗脱剂进行纯化,得到产物Alkynyl-Rapa。
(2)合成SS31-DVED-PEG6-N3:将Ramage Amide AM resin树脂溶胀活化,使用20%吡啶的DMF溶液脱去树脂上的Fmoc,将1倍量的Fmoc-Phe-OH与1~2倍量的PyBop和2~5倍量的DIPEA溶于DMF后加入固相反应柱中,于室温下反应1-2h。待反应完成后,除去溶剂,向固相反应柱中加入含20%吡啶的DMF于室温下处理5-15min以脱去Fmoc-Phe-OH上的Fmoc并用DMF和二氯甲烷多次洗涤。重复以上步骤,按照所设计好的序列连接氨基酸形成肽链。待肽链连接完毕后,使用20%吡啶的DMF脱去末端氨基上的Fmoc保护基团,然后将1~2倍量的N3-PEG6-CH2CH2COOH、1~2倍量的PyBop和2~5倍量DIPEA溶于DMF后在冰浴环境下加入固相反应柱中,继续反应1-2h。待反应结束后,使用DMF和甲醇多次洗涤,最后用裂解液将产物从固相反应树脂上切割下来并脱去所有保护基团,通过制备液相进行纯化,得到产物SS31-DVED-PEG6-N3。
(3)将1倍量合成的Alkynyl-Rapa和1倍量的SS31-DVED-PEG6-N3共同溶于甲醇中,加入1~5倍量的CuSO4和1~5倍量的抗坏血酸钠,于室温下超声反应1-2h,反应结束后使用0.45μm的滤膜过滤除去不溶物,最后纯化,得到终产物SS31-DVED-Rapa。
上述SS31-Rapa偶联物(SS31-DVED-Rapa)的合成方法,其中
所述步骤(1)中,在三氟甲磺酸-2-丙炔基氧基乙酯的合成中,优选1~2倍量的2,6-二甲基吡啶和1~2倍量的三氟甲磺酸酐,反应2h;在Alkynyl-Rapa的合成中,优选3~5倍量的三氟甲磺酸-2-丙炔基氧基乙酯和5倍量的DIPEA,在60℃下反应2h。
所述步骤(2)中,在合成酰胺键的反应中,优选1倍量的PyBop和4倍量DIPEA,反应2h;使用含有20%吡啶的DMF溶液脱去Fmoc保护基团的过程中,优选反应5min。
所述步骤(3)中,click反应中,优选加入4倍量的CuSO4和4倍量的抗坏血酸钠,超声反应2h。
一种所述的红细胞搭便车型偶联物的应用,所述偶联物或其盐在制备药物递送载体中的应用。
一种所述的红细胞搭便车型偶联物的应用,所述偶联物或其盐在制备预防或治疗氧化应激相关疾病药物中的应用。
本发明的优势在于:
(1)使用的SS31-Rapa偶联物的合成过程采用成熟的反应技术,操作过程明确,易于制备。
(2)相比与传统的红细胞搭便车类制剂,本发明中的SS31-Rapa偶联物无需后续处理,可直接增溶后注射,在血液内蓄积于红细胞中,完成红细胞搭便车的过程。无需纳米制剂的制备和引入其他辅料。
(3)偶联物结构中的Rapa结构不仅仅可以用来结合红细胞内部的FKBP靶点,还可以抑制mTOR通路刺激自噬过程,清除细胞内受损的细胞器,尤其是受损的线粒体这一ROS最主要的来源,与SS31发挥协同治疗作用。增强其在治疗氧化应激损伤相关疾病中的疗效。
(4)本发明中的SS31-Rapa偶联物具有在红细胞中的蓄积能力,同时该偶联物可以与红细胞发生动态结合从而实现红细胞搭便车,在包载到红细胞内以后可以释放出来。此外,本发明所述的SS31-Rapa偶联物具有智能释放、长循环、低毒性和高效治疗氧化应激损伤的效果为开发氧化应激损伤微环境智能响应型药物递送系统提供了新的策略和更多的选择。满足了临床中对于急性氧化应激损伤相关疾病高效治疗制剂的迫切需求。
附图说明
图1为本发明实施例1的SS31-DVED-Rapa偶联物的质谱图和1H-NMR谱图。
图2为本发明实施例2的全血血浆比(B/P)检测结果图。
图3为本发明实施例3的SS31-DVED-Rapa偶联物与红细胞动态结合试验结果图。
图4为本发明实施例4的SS31-DVED-Rapa偶联物红细胞载药后释放试验结果图。
图5为本发明实施例5的SS31-DVED-Rapa偶联物在caspase-3刺激下释放SS31试验结果图。
图6为本发明实施例6的SS31-DVED-Rapa偶联物生物相容性试验结果图。
图7为本发明实施例7的SS31-DVED-Rapa偶联物促进自噬过程试验的结果图。
图8为本发明实施例8的SS31-DVED-Rapa偶联物的体内血药浓度-时间曲线。
图9为本发明实施例9的SS31-DVED-Rapa偶联物治疗顺铂诱导的急性肾损伤实验图。
图10为本发明实施例9的SS31-DVED-Rapa偶联物治疗缺血-再灌注诱导的急性肾损伤实验图。
图11为本发明实施例10的SS31-DVED-Rapa偶联物治疗脑缺血再灌注损伤实验结果图。
具体实施方法
下面通过实施例的方法进一步说明本发明,但并不因此将发明限制在所述的实施例范围中。
本发明偶联物是将药动学性质较差的抗氧化肽与Rapa连接成为偶联物可以使这些药动学性质较差的药物具备“红细胞搭便车”的能力,蓄积于红细胞这个“庇护所”中,有效地避免其被血浆代谢酶降解和被免疫细胞清除。除此之外,偶联物中的Rapa结构域还可以通过抑制mTOR通路达到促进自噬作用的目的,促进降解细胞内异常的蛋白和受损的细胞器,尤其是受损的线粒体,这一亚细胞器为ROS主要的来源,防止有害物质的积累;与偶联物中释放出来的抗氧化肽起到协同作用,降低由ROS引起的氧化应激损伤。
进一步的说,本发明利用偶联物中Rapa结构域和红细胞中高表达的FKBP形成稳定的二元复合物,使结构中半衰期较短的抗氧化肽SS31蓄积于红细胞内进而避免其被血液内的代谢酶降解或被吞噬细胞清除,以此来改善其药动学特性,同时在偶联物结构中引入氧化应激损伤中因发生细胞凋亡而表达升高的半胱天冬氨酸酶caspase-3敏感键实现智能响应性释放。此外,偶联物中的Rapa结构域可以刺激机体内的自噬作用,清除受损的细胞器,尤其是受损的线粒体这一ROS的主要来源,与偶联物中释放出的SS31发挥协同抗氧化作用,提高其对氧化应激引起的相关疾病的治疗效果。
下述实施例中倍量以化学反应投料时计算投料比时使用的计量单位,均为摩尔比。
实施例1:Caspase-3敏感型SS31-Rapa偶联物(SS31-DVED-Rapa)的合成.
首先合成2-丙炔基氧基乙基化修饰的Rapa(Alkynyl-Rapa):
将1倍量丙炔醇乙氧基化合物溶于适量二氯甲烷中,在-50℃下逐滴加入2倍量的2,6-二甲基吡啶和2倍量的三氟甲磺酸酐,并在-10℃下反应2h。反应结束后,依次用乙酸乙酯和正己烷1:1(v/v)的有机溶剂和饱和NaCl萃取反应液,收集有机层,并用饱和NaCl洗涤3次,使用无水Na2SO4干燥有机层过夜,然后通过旋转蒸发法除去有机溶剂,通过硅胶柱层析法分离,洗脱剂为正己烷:乙酸乙酯(9:1(v/v)),得到产物三氟甲磺酸-2-丙炔基氧基乙酯。
接下来合成Alkynyl-Rapa:
将1倍量的Rapa溶于氯仿中,在-10℃下加入5倍量的三氟甲磺酸-2-丙炔基氧基乙酯和5倍量的DIPEA,在N2保护中以60℃的反应温度反应2h。反应结束后,用乙酸乙酯和水萃取反应液,收集有机层,并用饱和NaCl洗涤3次,使用无水Na2SO4干燥有机层过夜,然后通过旋转蒸发法除去有机溶剂,通过硅胶柱层析法分离,洗脱剂为正己烷:乙酸乙酯(2:1(v/v)),得到Alkynyl-Rapa。
SS31-DVED-PEG6-N3的合成:
首先将适量Ramage Amide AM resin树脂溶胀后用含20%哌啶的DMF溶液浸泡5min脱除树脂上的Fmoc保护基。称取1倍量的Fmoc-Phe-OH溶于80mL的DMF中,在冰浴中加入1倍量的PyBop和4倍量的DIPEA,待完全溶解后,加入到固相反应柱中室温反应1h,通过茚三酮法检测是否为阴性来检测反应是否完成。反应结束后使用旋转蒸发法除去反应溶剂,用100mL的DMF洗涤并加入含20%哌啶的DMF溶液100mL,反应5min,脱去氨基上的Fomc保护基团,待反应结束后分别用适量DMF洗涤3次,二氯甲烷洗涤两次。接下来,按照多肽序列依次从C端到N端进行连接,直至Fmoc-Asp(OtBu)-OH;其中Asp、Glu、dimethylTyr、D-Arg、Lys的侧链保护基分别是OtBu、OtBu、tBu、Pbf、Boc;所有的氨基酸都用Fmoc保护α位氨基。肽链连接完成后加入含有20%哌啶的DMF溶液反应5min除去肽链的Fmoc保护基,将1倍量的N3-PEG6-CH2CH2COOH溶于适量DMF中,加入固相反应柱中,并向反应中加入1倍量的PyBop,在冰浴条件下缓慢加入4倍量的DIPEA,并在冰浴条件下持续搅拌15min后撤去冰浴,继续在室温下反应2h。通过茚三酮检测法是否为阴性来判断反应是否完全。反应结束后,抽干反应液,用100mL的DMF洗涤3次,然后用甲醇再洗涤3次。待固相合成结束后,通过裂解液(TFA:三异丙基硅烷:水=95:2.5:2.5)与直链肽树脂反应,得到脱出所有侧链保护基的多肽粗产物,并通过制备液相纯化得到SS31-DVED-PEG6-N3。
SS31-DVED-Rapa的合成:
将1倍量的Alkynyl-Rapa和1倍量的SS31-DVED-PEG6-N3溶于适量甲醇中,加入2倍量的CuSO4和2倍量的抗坏血酸钠,充分混合均匀,避光超声2h,待反应结束,使用0.45μm的滤膜过滤反应液除去不溶物,并使用制备液相分离提纯得到SS31-DVED-Rapa。
采用质谱法和核磁工作氢谱法来确定实施例1中前药的结构,结果如图1所示。核磁共振测试选用的溶剂为DMSO-d6,波谱解析结果如下:
(A)HR-ESI-MS:m/z[M+2H]2+calculated for C121H189N17O36:1228.173509,found1228.175501.(B)1H-NMR(600MHz,DMSO-d6)δ8.24(dd,J=16.9,7.6Hz,2H),8.10(d,J=8.7Hz,1H),8.03(s,1H),7.99(d,J=7.7Hz,1H),7.91(d,J=7.9Hz,1H),7.8(d,J=8.1Hz,1H),7.73(t,J=8.8Hz,1H),7.39(m,2H),7.17-7.26(m,5H),7.08(s,1H),6.40(dd,J=14.6,11.2Hz,1H),6.31(s,2H),6.20-6.24(m,1H),6.10-6.15(m,2H),5.44(dd,J=14.9,9.6Hz,1H),5.09(d,J=10.1Hz,1H),4.96-4.99(m,1H),4.94(d,J=9.3Hz,1H),4.50-4.57(m,8H),4.43(td,J=8.4Hz,1H),4.28-4.31(m,3H),4.20(q,J=7.5Hz 1H),4.14(dd,J=8.5,6.4Hz,1H),4.01-4.02(m,2H),3.96(d,J=4.5Hz,1H),3.81(t,J=5.3Hz,2H),3.48-3.66(m,30H),3.32(s,3H),3.24-3.28(m,1H),3.15(s,3H),3.05(s,3H),2.63-3.02(m,14H),2.34-2.41(m,4H),2.18-2.24(m,2H),2.15(s,6H),1.82-1.96(m,6H),1.74(s,3H),1.04-1.72(m,35H),0.97(d,J=6.5Hz,3H),0.85(d,J=6.5Hz,3H),0.82(d,J=6.5Hz,3H),0.79(d,J=6.7Hz,3H),0.77(dd,J=6.8,2.9Hz,6H),0.73(d,J=6.7Hz,3H).
实施例2:SS31-DVED-Rapa的全血血浆比测定试验
精密称取2.5mg上述获得偶联物SS31-DVED-Rapa,加入到200μL的DMSO中充分溶解制成5mM的储备液,然后加入到适量的全血中,使血液中的SS31-DVED-Rapa终浓度为50μM,37.5μM和25μM。同时配制含有50μM,37.5μM和25μMSS31的全血样品作为对照。在37℃下孵育1h后采用离心法获得全血样品中的血浆,使用ZnSO4溶液将红细胞破碎,将全血和血浆样品除去蛋白后使用高效液相色谱法检测全血及血浆中SS31-DVED-Rapa和SS31的含量,计算全血血浆比(B/P)。
如图2所示,相比与游离的SS31,SS31-DVED-Rapa偶联物的全血血浆比的显著提高,在浓度为50μM,37.5μM和25μM时,偶联物的B/P分别为7.24、9.50和10.52,相比与游离SS31分别提高了5.6、6.9和7.4倍。这表明,相比与游离的抗氧化剂SS31,与Rapa偶联后的SS31-DVED-Rapa会更多地分布在红细胞中,进而避免被代谢酶降解。
实施例3:SS31-DVED-Rapa与红细胞的动态结合验证试验
首先使用红细胞提取试剂盒以梯度离心法分离全血中的红细胞,得到红细胞悬液。精密称取2.5mg上述获得偶联物SS31-DVED-Rapa,加入到200μL的DMSO中充分溶解制成5mM的储备液。使用血细胞计数板对分离的红细胞悬液计数,并用PBS(pH=7.4)将红细胞悬液稀释到1×108个红细胞/mL。将5mM的SS31-DVED-Rapa储备液加入到1mL红细胞悬液中,使得SS31-DVED-Rapa的终浓度为50μM。在37℃下孵育1h,孵育结束后以2500rpm的转速在室温下离心5min弃去上清,以新鲜PBS缓冲液将红细胞清洗3次,并使用ZnSO4溶液将红细胞破碎,除去蛋白后通过高效液相色谱法检测红细胞中SS31-DVED-Rapa的含量。
首先将红细胞与100μM的Rapa共孵育2h来预先结合红细胞内的FKBP结合位点,然后再与SS31-DVED-Rapa进行共孵育,作为对照。
除此之外,还将包载过SS31-DVED-Rapa的红细胞与含有100μM的Rapa共孵育2h来考察SS31-DVED-Rapa通过与红细胞内的FKBP结合来实现红细胞搭便车这一过程是否为动态可逆。
如图3所示,经过Rapa预处理后,红细胞内的FKBP结合位点被Rapa部分占据。再与SS31-DVED-Rapa偶联物共孵育后红细胞包载的偶联物的量显著低于未经处理的红细胞。这表明SS31-DVED-Rapa偶联物的红细胞搭便车作用中,偶联物结构中的Rapa基团与红细胞中的FKBP结合起着关键作用。此外,在红细胞包载了SS31-DVED-Rapa偶联物后,再次与Rapa进行共孵育,从结果中可以看出红细胞中偶联物的含量明显下降,这表明,在结合了偶联物再结合了红细胞内的FKBP受体后可以被后来的Rapa竞争替代,进而说明偶联物与红细胞的搭便车结合为动态可逆过程。
实施例4:SS31-DVED-Rapa包载入红细胞后的释放试验。
首先使用红细胞提取试剂盒以梯度离心法分离全血中的红细胞,得到红细胞悬液。精密称取2.5mg SS31-DVED-Rapa,加入到200μL的DMSO中充分溶解制成5mM的储备液。使用血细胞计数板对分离的红细胞悬液计数,并用PBS(pH=7.4)将红细胞悬液稀释到4×108个红细胞/mL。将5mM的SS31-DVED-Rapa储备液加入到1mL红细胞悬液中,使得SS31-DVED-Rapa的终浓度为50μM。在37℃下孵育1h,孵育结束后以2500rpm的转速在室温下离心5min弃去上清,以新鲜PBS缓冲液将红细胞清洗3次。将洗涤好的载有偶联物的红细胞重悬于1mLPBS(pH=7.4)缓冲液中,于37℃下孵育,在4h、8h和12h将红细胞悬液以2500rpm的转速在室温下离心,取上清液,并用高效液相色谱法检测上清液中的SS31-DVED-Rapa偶联物含量。
如图4所示,包载过SS31-DVED-Rapa偶联物的红细胞在12h内可以释放出其内部包载的约23.2%的偶联物,这表明,偶联物可以从红细胞中释放出来,发挥治疗作用。
实施例5:SS31-DVED-Rapa的体外SS31释放试验
以PBS(pH=7.4)溶液为释放介质,并在释放介质中加入1μg/mL的caspase-3考察其在细胞凋亡条件下释放SS31的情况。精密称取2.5mg SS31-DVED-Rapa,加入100μL的DMSO充分溶解制成10mM的储备液,然后加入到含有caspase-3的PBS(pH=7.4)溶液中,使终浓度为100μM。在37℃下孵育,于2h、4h、6h、8h、10h、和12h取样通过高效液相色谱法测定释放出的SS31的浓度,来考察SS31-DVED-Rapa在caspase-3作用下的SS31释放情况。
如图5所示,在caspase-3的刺激下,经过12h的孵育,约有50%的SS31从SS31-DVED-Rapa偶联物中响应性释放出来。
实施例6:SS31-DVED-Rapa的生物相容性试验
采用MTT法考察SS31-DVED-Rapa对人肾小管上皮(HK-2)细胞的细胞毒性来评价SS31-DVED-Rapa的生物相容性。将状态良好的HK-2细胞消化,用MEM培养基稀释至15000cells/mL的细胞密度,吹打均匀后于96孔板中每孔加入细胞悬液200μL,置于细胞培养箱中,在37℃,5%CO2的环境下孵育24h使其贴壁。待细胞贴壁后,弃去原有的培养基,重新加入含有5、10、25、50和100μM浓度SS31-DVED-Rapa的MEM培养基。受试溶液每孔加入200μL,每个浓度3个平行孔。对照组,即不加待测药物,单一补加200μL培养基,置于细胞培养箱中孵育48h。孵育结束后,将96孔板取出,每孔加入5mg/mL MTT溶液20μL,在细胞培养箱中继续孵育4h后甩板,并将96孔板倒扣于滤纸上充分吸干残留液体,每孔中加入200μL的DMSO于振荡器上振荡15min以溶解蓝紫色结晶物。设定调零孔(只含有200μL DMSO)。使用酶标仪在570nm处测定各孔调零后的吸光度值。
如图6所示,HK-2细胞在与浓度高达100μM的SS31-DVED-Rapa偶联物共同孵育48h后细胞存活率依然高于80%,这表明,SS31-DVED-Rapa具有良好的生物相容性。
实施例7:SS31-DVED-Rapa偶联物促进自噬过程试验
使用MEM培养基将HK-2细胞培养至对数生长状态,使用胰酶消化并用MEM培养基稀释至50000cells/mL的细胞密度,吹打均匀后于6孔板中每孔加入细胞悬液4mL,在37℃,5%CO2的环境下孵育24h使其贴壁。待细胞贴壁后,弃去原有的培养基。然后分别给予空白MEM培养基、含有5μg/mL顺铂的MEM培养基、含有5μg/mL顺铂和20μg/mL SS31的MEM培养基、含有5μg/mL顺铂和28μg/mLRapa的MEM培养基、含有5μg/mL顺铂,20μg/mL SS31和28μg/mLRapa的MEM培养基和含有5μg/mL顺铂和76μg/mL SS31-DVED-Rapa偶联物的MEM培养基(等效SS3120μg/mL和Rapaμg/mL)。继续在37℃,5% CO2的环境下孵育24h。孵育结束后弃去培养基并加入适量PBS,使用细胞刮刀收集细胞,用Ripa裂解液将细胞裂解后,分别用BCA蛋白定量试剂盒和Elisa试剂盒检测蛋白总量、自噬相关的LC3 II和p62蛋白的含量。
如图7所示,自噬水平提高后,往往伴随着LC3 II表达水平的上升和p62蛋白表达水平的下降。在顺铂诱导氧化应激损伤发生后,HK-2细胞内的自噬保护机制被激活,自噬相关蛋白表达水平高于正常的HK-2细胞。由于Rapa是mTOR抑制剂可以通过抑制mTOR通路来促进自噬过程。因此,当给予含有Rapa及Rapa结构域的SS31-DVED-Rapa偶联物时,进一步升高的LC3 II蛋白水平和进一步降低的p62蛋白水平表明细胞内的自噬水平经过刺激后进一步提高。当自噬过程被激活后,其可以通过形成自噬体来将受损的细胞器和蛋白等废物转移至溶酶体降解,进而减少这些损伤结构中ROS的产生,可以于偶联物中释放的抗氧化肽SS31发挥协同作用,提高其治疗氧化应激损伤的效果。
实施例8:SS31-DVED-Rapa的药代动力学研究
取体重在200-250g之间的雄性Wistar大鼠,随机分为2组,给药前禁食12h,自由饮水。分别静脉注射给予使用聚氧乙烯蓖麻油和乙醇共同增溶后的SS31-DVED-Rapa和游离的SS31,给予的药物剂量等效为SS31 2mg/kg。于规定的时间点采集全血血样,使用ZnSO4溶液破坏红细胞,并用冷乙腈除去样品中的蛋白,通过高效液相色谱仪测定各个时间点的血药浓度。
结果如图8所示,SS31被迅速地从血液中清除。相比之下,作为Rapa偶联物的SS31-DVED-Rapa由于具有红细胞搭便车的能力,可以蓄积于红细胞中,将红细胞作为药物的庇护所,从而避免药物被血液内的代谢酶降解,这使得SS31-DVED-Rapa相比于SS31循环时间明显延长。经过DAS计算的药动学参数如表1所示,SS31-DVED-Rapa显著延缓了SS31的代谢,其体内循环半衰期(t1/2)达到了SS31的6.9倍。此外,相比于SS31,SS31-DVED-Rapa还具有更高的AUC0-48h和MRT0-48 h以及更低的血浆清除率。综上结果所示,本发明中的雷帕霉素偶联物可以显著改善抗氧化药物SS31的药动学性质,延长其体内循环时间。
表1.SS31和SS31-DVED-Rapa的药动学参数。
实施例9:SS31-DVED-Rapa对于顺铂诱导的急性肾损伤的治疗效果试验
取体重在18-22g的雄性balb/c小鼠,随机分为7组,在给药前禁食12h,自由饮水。称取适量顺铂用生理盐水溶解,配置成浓度为2mg/mL的溶液,按照20mg/kg的剂量腹腔注射到balb/c小鼠体内,称量体重,观察30min后随机分组,每组5只,分别给予生理盐水、SS31、Rapa、SS31与Rapa共同治疗和SS31-DVED-Rapa,按照SS31与Rapa计算,给药剂量分别为2mg/kg和2.8mg/kg。以腹腔注射等量生理盐水并使用静脉注释生理盐水治疗的模型作为对照组。在给药72h后称量模型小鼠的体重并将小鼠处死,获取小鼠血液和双侧肾脏。将血液离心后取血清用于检测血清肌酐(Cre)和尿素氮(BUN),获得的肾脏标本用检测肾脏内丙二醛(MDA)、超氧化物歧化酶(SOD)、IL-6和TNF-α的水平。
如图9中所示的结果,相比于使用SS31、Rapa和SS31与Rapa联合治疗,在给予AKI小鼠模型SS31-DVED-Rapa治疗后小鼠表现出了更轻微的体重下降(图9A)。在改善AKI发生后肾脏功能方面,SS31-DVED-Rapa相比于SS31等其他治疗剂可以更显著地降低CRE和BUN的水平(图9B和9C)。在降低肾脏内氧化应激水平方面,经过SS31-DVED-Rapa治疗的模型小鼠相比于使用SS31、Rapa和SS31与Rapa联合治疗的小鼠表现出更高的肾脏内SOD活性和更低的MDA水平(图9D和9E)。在炎症浸润方面,相比于给予SS31等其他治疗剂的小鼠模型,使用SS31-DVED-Rapa治疗的小鼠肾脏中促炎性相关的细胞因子TNF-α和IL-6的水平下降更加明显(图9F和9G)。综合以上结果,SS31-DVED-Rapa可以显著提高SS31在治疗顺铂诱导的急性肾损伤中的效果。
实施例10:SS31-DVED-Rapa对于缺血-再灌注(I&R)诱导的急性肾损伤的治疗效果试验
在缺血再灌注诱导的急性肾损伤模型建立过程中,首先将22-25g的雄性KM小鼠置于恒温板上,麻醉并备皮,沿腹中线剪开皮肤暴露出器官,找到双侧肾脏,用消毒后的微型止血夹夹住双侧肾蒂40min造成缺血,然后松开止血夹使血液再灌注。完成造模后,将腹中线伤口缝合,做好消毒后用纱布覆盖伤口。称量体重,观察30min后随机分组,每组5只,分别给予生理盐水、SS31、Rapa、SS31与Rapa共同治疗和SS31-DVED-Rapa,按照SS31与Rapa计算,给药剂量分别为2mg/kg和2.8mg/kg。在对照组中,对目标动物采取仅剪开腹中线并缝合,不夹持两侧肾蒂作为假手术过程并通过尾静脉给予生理盐水。72小时之后,称量小鼠体重,然后将小鼠处死,取小鼠的血液约1mL于促凝采血管中,离心得血清,测量其中的血清肌酐(Cre)和尿素氮(BUN)水平。另取小鼠肾脏,检测其中超氧化物歧化酶(SOD)、丙二醇(MDA)、肿瘤坏死因子-α(TNF-α)和白细胞介素-6的水平(IL-6)。
如图10中所示的结果,相比于使用SS31、Rapa和SS31与Rapa联合治疗,在给予AKI小鼠模型SS31-DVED-Rapa治疗后小鼠并未表现出了任何的体重降低现象(图10A)。在改善AKI发生后肾脏功能方面,给予SS31-DVED-Rapa治疗可以最显著地降低CRE和BUN的水平(图10B和10C)。在降低肾脏内氧化应激水平方面,AKI小鼠模型在经过SS31-DVED-Rapa治疗后相比于使用其他方式治疗的小鼠表现出更高的肾脏内SOD活性和更低的MDA水平(图10D和10E)。在降低炎症浸润水平方面,相比于给予SS31等其他治疗方式,使用SS31-DVED-Rapa治疗的小鼠肾脏中TNF-α和IL-6两种促炎性细胞因子的水平下降更加明显(图10F和10G)。综合以上结果,SS31-DVED-Rapa可以显著提高SS31在治疗缺血-再灌注诱导的急性肾损伤中的效果。
实施例11:SS31-DVED-Rapa对于脑缺血再灌注损伤的治疗效果试验
用线栓法建立短暂性大脑中动脉缺血再灌注模型(MCAO/R model)。首先将雄性C57BL/6小鼠(22-25g)用小动物气体麻醉机完全麻醉小鼠,然后用1.5%异氟醚保持麻醉。分离右颈总动脉(RCCA)、右颈外动脉(RECA)和右颈内动脉(RICA)后,用电凝笔结扎RECA的远端,然后将硅涂层尼龙线从RECA插入大脑中动脉,旨在阻断RMCA的血液供应。产生缺血2h后,将尼龙线逐渐抽出进行再灌注并结扎RECA,随后进行给药。分别给予生理盐水SS31与Rapa共同治疗和SS31-DVED-Rapa,按照SS31与Rapa计算,给药剂量分别为2mg/kg和2.8mg/kg。在对照组中,对假手术组采用尾静脉给药的方式给予生理盐水进行处理。在给药处理24h后,对小鼠模型进行改良的神经学评分,然后将小鼠处死,取脑组织进行TTC染色和脑含水量分析。
结果如图11中所示,在神经学评分结果中,MCAO/R组的小鼠明显表现出神经功能缺损,具体表现为出现盘旋运动、自发运动减少和严重的爪弯曲现象,经过SS31-DVED-Rapa治疗后,小鼠神经功能缺陷的得到显著缓解(图11B)。在脑梗死面积方面,经过手术造模后,MCAO组的小鼠的脑梗死面积达到了44.13%,经过SS31-DVED-Rapa治疗后,造模小鼠的梗死面积下降为16.33%,相比于造模组有了显著的降低且明显低于SS31和Rapa共同治疗组(梗死面积约为27.11%)(图11A和11C)。在脑含水量分析试验中,MCAO/R组的小鼠脑部具有较高的含水量,经过SS31-DVED-Rapa治疗后,损伤脑部的含水量显著降低,达到了和假手术对照组相似的水平(图11D)。综合以上结果,SS31-DVED-Rapa可以显著减少脑缺血再灌注引起的脑部损伤。
结果表明,本发明偶联物可以显著提高抗氧化肽SS31在红细胞内的蓄积水平,并且偶联物在红细胞上的搭便车的功能是动态可逆的,在包载进红细胞后,该偶联物可以自动脱离并释放出来以发挥治疗效果。本发明偶联物具有显著的caspase-3敏感释放,可以选择性地在细胞凋亡部位释放抗氧化肽SS31。由于结构中含有Rapa结构域,该偶联物可以有效地促进自噬过程来发挥清除ROS的作用。在生物相容性方面,偶联物具有较低的毒性。由于偶联物具有红细胞搭便车的功能,可以蓄积于红细胞内,进而避免被代谢酶所降解,相比于SS31,该偶联物具有更好的药动学性质。此外,偶联物还可以有效提高SS31在治疗氧化应激损伤中的药效,其可以显著改善急性肾损伤发病时肾脏的功能和肾脏微环境以及降低脑缺血再灌注后的脑部损伤。
综上可见本发明中的偶联物可以用于制备氧化应激损伤微环境智能响应释放型药物递送系统。可以改善SS31等抗氧化性肽的药动学性质,并提高其对于氧化应激损伤相关疾病的治疗效果。
Claims (9)
1.一种红细胞搭便车型偶联物,其特征在于:偶联物结构为S-C-L-R,其中,S为抗氧化功能的多肽,C为敏感型连接臂,L为Linker,R为能够与红细胞的结合蛋白靶点结合的物质;
或,偶联物的盐。
2.根据权利要求1所述的红细胞搭便车型偶联物,其特征在于:所述抗氧化功能的多肽为SS31(Arg-Dmt-Lys-Phe-NH2)、SBT-20(Phe-Arg-Phe-Lys-NH2)、SBT-68(Arg-Dmt-Ala-Phe-NH2)、SBT-100(Arg-Dmt-His-Phe-NH2)或SBT-131(Orn-Dmt-Lys-Phe-NH2)。
3.根据权利要求1所述的红细胞搭便车型偶联物,其特征在于:所述敏感型连接臂为二硫醚衍生物、基质金属蛋白酶或组织蛋白酶响应肽;其中,二硫醚衍生物为酮缩硫醇;基质金属蛋白酶响应肽为GPLGLAGC肽段;组织蛋白酶响应肽为DVED肽段。
4.根据权利要求1所述的红细胞搭便车型偶联物,其特征在于:所述Linker的结构中一端含与自裂解结构相连的活性位点,另一端含能够与红细胞内的结合蛋白靶点结合的物质结合的活性位点,且,循环长度为PEG4-PEG10。
5.根据权利要求4所述的红细胞搭便车型偶联物,其特征在于:所述敏感型连接臂为二硫醚衍生物时,Linker中与其结合一端的活性位点为氨基或羟基,另一端结合位可以与红细胞内结合物质连接,且,循环长度为PEG4-PEG10;敏感型连接臂为基质金属蛋白酶敏感肽时Linker中与其结合一端的活性位点为氨基或羟基,另一端结合位点可以与红细胞内结合物质连接,且,循环长度为PEG4-PEG10;敏感型连接臂为组织蛋白酶响应肽时Linker中与其结合一端的活性位点为氨基或羟基,另一端结合位点可以与红细胞内结合物质连接,且,循环长度为PEG4-PEG10。
6.根据权利要求1所述的红细胞搭便车型偶联物,其特征在于:所述能够与红细胞内的结合蛋白靶点结合的物质为雷帕霉素、他克莫司(FK506)、吡美莫司或依维莫司。
7.根据权利要求1-6任意一项所述的红细胞搭便车型偶联物,其特征在于:所述抗氧化功能的多肽为SS31、SBT-20或SBT68;所述敏感型连接臂为酮缩硫醇、GPLGLAGC肽段或DVED肽段;所述Linker为PEG6、PEG8或PEG10;所述能够与红细胞内的结合蛋白靶点结合的物质为雷帕霉素或他克莫司。
8.一种权利要求1所述的红细胞搭便车型偶联物的应用,其特征在于:所述偶联物或其盐在制备药物递送载体中的应用。
9.一种权利要求1所述的红细胞搭便车型偶联物的应用,其特征在于:所述偶联物或其盐在制备预防或治疗氧化应激相关疾病药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311267933.2A CN117257915A (zh) | 2023-09-28 | 2023-09-28 | 一种红细胞搭便车偶联物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311267933.2A CN117257915A (zh) | 2023-09-28 | 2023-09-28 | 一种红细胞搭便车偶联物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117257915A true CN117257915A (zh) | 2023-12-22 |
Family
ID=89200513
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311267933.2A Pending CN117257915A (zh) | 2023-09-28 | 2023-09-28 | 一种红细胞搭便车偶联物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117257915A (zh) |
-
2023
- 2023-09-28 CN CN202311267933.2A patent/CN117257915A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111777671B (zh) | 一种长效的psd-95抑制剂 | |
JP5809286B2 (ja) | クコアミンbの塩の製造方法 | |
JP2001522817A (ja) | オピオイドと内因性担体の新規コンジュゲート | |
EP2994152B1 (de) | Konjugate zum schutz vor nephrotoxischen wirkstoffen | |
CN111560052B (zh) | 一种羊肚菌源抗氧化肽及其制备方法和应用 | |
CN103965287A (zh) | 一种次血红素三肽及其制备方法和用途 | |
CN112979755B (zh) | pH响应载药自组装形成水凝胶的多肽、制备方法及用途 | |
JP2008507580A (ja) | 反応性酸素種およびカルボニル種を阻害し得る組成物 | |
EP2016094A1 (en) | Novel analogues of antimicrobial and anticancer peptide synthesized and produced from gaegurin 5 | |
CN117257915A (zh) | 一种红细胞搭便车偶联物及其制备方法和应用 | |
CN101402676A (zh) | 聚乙二醇类修饰的杀菌/中和内毒素多肽及其制备方法和应用 | |
JPS63198698A (ja) | 新規ペプチド、その製法およびそれを含有する医薬組成物 | |
CN113713117A (zh) | 一种白蛋白结合型肿瘤环境响应型抗肿瘤前体药物及其制备方法和应用 | |
CN101265292B (zh) | 多肽类物质、其制备方法及其用途 | |
KR100213897B1 (ko) | 신생혈관유도현상 억제 활성을 갖는 계피 유래의 신남 알데하이드 유도체, 이의 제조방법 및 이를 함유하는 조성물 | |
CN116808231B (zh) | 一种细胞穿膜肽偶联舒必利前药体系以及制备方法和应用 | |
CN109776787A (zh) | 多臂靶向偶联物 | |
EP3333177B1 (en) | Multi-target compound with anticoagulation and antiplatelet activity, preparation method therefor, and use thereof | |
CN103012555A (zh) | 具有组织保护活性的新多肽的制备方法及在治疗中的应用 | |
CN107586316A (zh) | 具有血栓溶解活性的多肽 | |
CN113952468B (zh) | 一种治疗心肌缺血再灌注损伤的环孢菌素a纳米药物 | |
CN108948158B (zh) | 四连接素模拟肽tnp及其应用 | |
WO2023169550A1 (zh) | 用于预防和/或治疗肾纤维化的多肽化合物 | |
KR100615971B1 (ko) | 개구린 5로부터 합성 및 제조된 항암 펩타이드 유도체 | |
CN115490684A (zh) | 3S-1,2,3,4-四氢-β-咔啉-3-甲基-氨基酸及其制备、抗血栓活性和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |